A diverse group of small-cap companies spanning biotechnology, artificial intelligence infrastructure, supply chain authentication, and advanced energy storage is drawing increased attention as sector-specific catalysts and macro trends continue to…
Kartoon Studios (NYSE: TOON) is gaining significant investor attention as momentum builds across the media sector following reports that investors have approved a major transaction involving Warner Bros. Discovery (NASDAQ:…
As the global race to scale artificial intelligence (AI infrastructure) accelerates, a critical constraint is beginning to reshape the industry: power availability. While much of the market remains focused on…
Kartoon Studios (NYSE: TOON) is entering what many investors view as a pivotal transition year, with its latest podcast appearance offering fresh insight into the company’s growth trajectory and 2026…
A renewed spotlight is forming around a group of small-cap healthcare companies as U.S. policy shifts toward accelerating research into psychedelic-based therapies for mental health disorders. Following a recent executive…
Kartoon Studios (NYSE: TOON) is entering what many investors see as a pivotal transition year—and the company’s latest podcast appearance is giving the market a closer look at what could…
A group of small-cap stocks is drawing increased attention this week as developments across defense technology, AI platforms, digital media, and data center infrastructure highlight a growing pipeline of catalyst-driven…
A new wave of small-cap catalyst-driven stocks is beginning to re-emerge on investor radar screens as multiple companies across semiconductors, biotech, and consumer growth sectors report developments that could signal…
A group of emerging NASDAQ stocks is gaining traction in 2026 as companies across AI infrastructure, creator economy tech, biotech innovation, and gaming execute strategic pivots into higher-growth markets. Names…
As the global race to treat metabolic dysfunction–associated steatotic liver disease (MASLD) and expand GLP-1 therapies accelerates, a critical challenge is emerging across the pharmaceutical industry: clinical trial infrastructure is…
